



EBU training 21 – 24 February 2022

Virtual Annual Interdisciplinary

Localized and Advanced Prostate Cancer Conference

Theme and aims

Oncourology Department of the National Cancer Institute (Lithuania) – the EBU-EAU certified host centre for Prostate cancer – has prepared online cycles to review diagnosis and treatment issue of localized and advanced (oligometastatic and metastatic) prostate cancer. During the virtual conference, lectures and workshops will be organized by doctors urologists, radiologists, medical oncologists, radiation oncologist and researchers. Virtual EBU training duration is 2 + 2 days. Guests can choose a cycle of their preference (1st and 2nd or 3rd-4th days) or participate in both cycles. The lectures will be broadcasted live. MDT meetings will be held every day to discuss the treatment plans for patients with localized and advanced prostate cancer. They will take place virtually but in real time - all participants will be able to ask questions, participate in the discussion and take part in decision making for the best treatment option of the patient. The 1st and 2nd training days are dedicated to discuss the standards of diagnosis and treatment of localized prostate cancer. Techniques of TRUS, histoscanning, transperineal and US/MRI guided prostate biopsies will be presented. There will be discussions about prostate imaging, new robotic systems for prostate cancer treatment, external beam radiotherapy, LDR and HDR. The diagnosis and treatment options of locally advanced non-metastatic and metastatic prostate cancer will be reviewed on the 3rd and 4th days of virtual EBU training. Lectures will present the diagnostic standards of advanced prostate cancer and systemic treatment for metastatic prostate cancer, more precisely: antiandrogen therapy (incl. new hormonal agents), chemotherapy and treatment of bone metastases with Radium 223. Detection of DNA mutations in prostate cancer, stereotactic therapy and treatment options of metastatic castration-sensitive and castration-resistant prostate cancer will be reviewed. We have asked every presenter to prepare few questions related to their presentations. In order to receive a certificate of attendance all participants will need to pass an online test which consists of these questions.

Conference program

07:30 – 09:00 Online registration

1st day - Diagnostics of localized prostate cancer, 21st February 2022

Moderators M.Trakymas, A. Žalimas

09:00 – 09:30	Welcome word. OECI and EBU-EAU Certified Host Centre for Prostate cancer. Prof. S. Jarmalaitė, Deputy Director for Research and Development of NCI, Acting Director of NCI
09:30 – 10:00	The results of Prostate cancer early diagnostic programme in Lithuania. A. Patašius, urologist, NCI
10:00 – 10:30	Clinical utility of germline prostate cancer genetics for disease management R. Janavičius, VUH SK
10:30 – 11:00	Ultrasound diagnostics of prostate cancer. Prostate biopsies NCI. A. Vėželis, B. Šikšniūtė, urologists, VUH SK
11:00 – 11:30	European consensus on imaging in prostate cancer. Discussion. Moderator M. Trakymas M. Trakymas, R. Briedienė, A. Čiuvašovas. radiologist, NCI
11:30 – 12:30	Multiparametric MRI for prostate cancer detection (PIRADS v2.1) and practical demonstration. R. Briedienė, radiologist, NCI
12:45 – 14:15	MDT discussion for the diagnostics and treatment of localized prostate cancer. Moderator M. Trakymas R. Briedienė, M. Trakymas, J. Ušinskienė, A. Čiuvašovas, radiologist V. Brasiūnas medical oncologist E. Janulionis, K. Slidevska radiation oncologist D. Dasevičius, pathologist A. Vėželis, A.Čekauskas, A. Žalimas, B. Šikšniūtė, urologists
14:30 – 15:00	Robot-assisted MRI guided prostate biopsy A. Čiuvašovas, radiologist, Republic Klaipeda hospital
15:00 – 15:20	Morphological diagnostics of prostate cancer. D. Dasevičius, pathologist, National Center of Pathology
15:20 – 16:00	Long COVID-19 and impact on urogenitary system: does this matter? Prof. A. Macas, anesthesiologist, Eglė Gulbinaitė and Ieva Dereškevičiūtė, LUHS

2nd day – Diagnostics and treatment of localized prostate cancer, 22nd February 2022

Moderators A. Žalimas, M.Trakymas

08:00 – 08:25	3D laparoscopic radical prostatectomy and new robotic systems for prostate cancer surgical treatment A. Čekauskas, urologist, VUH SK
08:25 – 08:50	Immunological differences between open and laparoscopic radical prostatectomy P. Bosas, urologist, NCI

08:50 – 9:20	Robot assisted radical prostatectomy with pelvic lymphadenectomy. Indications. B. Šikšniūtė, urologist, Perpignan hospital, France
09:20 – 09:40	Robotic assisted radical prostatectomy with Senhance platform R.Venckus; M. Jasenas, urologists, Klaipėda University Hospital
09:40 – 10:00	Open radical prostatectomy in NCI M. Kinčius, urologist, NCI
10:00 – 10:30	Radiology equipment for diagnosis and treatment of prostate cancer at the NCI J. Ušinskienė, radiologist, NCI
10:30 – 10:45	Nuclear medicine in prostate cancer detection. S. Tiškevičius, nuclear medicine physician, NCI
10:45 – 11:15	Prostate imaging workshop. R. Grigienė, radiologist, NCI
11:15 – 11:45	Histoscanning, tranperineal prostate biopsy. Presentation of clinical cases. A. Vėželis, B. Šikšniūtė, urologists, NCI
11:45 – 12:30	Prostate biopsy with MRI/US fusion M. Trakymas, interventional radiologist, NCI
12:30 – 14:00	MDT discussion for localized PC detection, indications for MRI/US fusion guided prostate biopsy. Radical prostate cancer treatment. Moderator M. Trakymas R. Briedienė, M.Trakymas, I. Naruševičiūtė, R. Briedienė, J. Ušinskienė, R. Grigienė, radiologists P. Bosas, A. Vėželis, B. Šikšniūtė, urologists E. Janulionis, A. Burneckis, K. Slidevska, Justinas Jonušas, radiation oncologists V. Brasiūnas, medical oncologist D. Dasevičius, pathologist
14:00 – 14:30	Comparing the Quality of Life of Men with Localized Prostate Cancer after Surgery, Radiation Therapy and Active Surveillance G. Bulotienė, psychiatrist, NCI
14:30 – 15:00	External beam radiotherapy in prostate cancer. K. Slidevska, radiation oncologist, NCI
15:00 – 15:30	Prostate cancer: LDR, HDR, Salvage HDR radiotherapy. E. Janulionis, radiation oncologist, NCI
15:30 – 16:00	Contemporary mpMRI based focal prostate cancer ablative therapy. M. Trakymas, radiologist, NCI
16:00 – 16:30	Prostate Cryotherapy. Indications, performance technique, presentation of clinical cases. A.Vėželis, B. Šikšniūtė, urologists NCI

3rd day - Diagnosis and treatment of oligometastatic and metastatic prostate cancer, 23rd February 2022

Moderator M. Kinčius

09:00 – 09:30	Focal therapy for prostate cancer care in 2022 A. Rakauskas, urologist, Lausanne university hospital
9:30 – 10:00	Imaging diagnosis and follow-up of advanced and oligo-metastatic prostate cancer PSMA

	PET/CT. M. Kalnina, M. Radzina, MD, PhD, Professor, radiologist, Head of Radiology Research laboratory, Riga Stradins University
10:00 – 10:30	DNA damage repair (DDR) gene mutations and liquid biopsy in prostate cancer T. Januškevičius, urologist, VUH SK
10:30 – 11:00	Non-invasive genetic prostate cancer diagnostics J. Gagilas, medical biologist, molecular diagnostics laboratory (Diagnolita).
11:00 – 11:30	MRT diagnosis of locally advanced prostate cancer I. Adomaitienė, radiologist, Affidea Lietuva
11:30 – 12:00	Non metastatic hormone resistant prostate cancer treatment. M. Kinčius, urologist, NCI
12:00 – 12:30	Side effects of systematic therapy and their management. V. Brasiūnas, medical oncologist, NCI
12:30 – 12:45	Local treatment of the primary tumor (RT) in the metastatic castration-sensitive/naïve situation. R. Steponavičienė, radiation oncologist, NCI
12:45 – 14:15	MDT discussion for the diagnostic and treatment of oligometastatic and metastatic prostate cancer. Moderator M. Kinčius S. Tiškevičius, I. Naruševičiūtė, I. Adomaitienė, radiologists J. Asadauskienė, V. Brasiūnas, A. Petrauskas, medical oncologists Ž. Kardelis, A. Vėželis, B. Šikšniūtė, A. Rakauskas, T. Januškevičius, urologists A. Burneckis, K. Slidevska, E. Janulionis, J. Jonušas radiation oncologists D. Dasevičius, pathologist
14:15 – 14:45	Local treatment of the primary tumour (surgery) in the metastatic castration-sensitive/naïve situation. Ž. Kardelis, urologist, NCI
14:45 – 15:15	Postoperative urinary incontinence: indications for surgical treatment. Diagnosis, selection of ligaments and sphincter. A. Patašius, urologist, NCI

4th day - Diagnosis and treatment of oligometastatic and metastatic prostate cancer, 24th February 2022

Moderator Ž. Kardelis

08:00 – 08:30	Imaging options for oligometastatic and metastatic prostate cancer R. Komiagienė, VUH SK
08:30 – 09:00	Imaging diagnosis of oligometastatic and metastatic prostate cancer PSMA PET/CT. A. Kornejeva, radiologist, North Estonia Medical Centre
09:00 – 09:30	Systematic therapy of the metastatic castration-sensitive/naïve prostate cancer. A. Petrauskas, medical oncologist, NCI
09:30 – 10:00	Prostate locally advanced and oligo-metastatic PCa radiotherapy Z. Ruduša, radiation oncologist, Riga East University Hospital, Oncology centre, Latvia

10:00 – 10:30	Systemic Therapy Options in Metastatic Castrate-Resistant Prostate Cancer A. Česas, Klaipeda university hospital
10:30 – 11:00	Indications for stereotactic radiotherapy for oligometastatic prostate cancer. M. Janavičius, radiation oncologist, NCI
11:00 – 11:30	Radium-223 therapy. Indications, case discussions. A. Vidrinskaitė, radiation oncologist, NCI
11:30 – 12:00	The role of hormone therapy in the treatment of prostate cancer Prof. M. Jievaltas, LUHS
12:00 – 14:45	MDT discussion of metastatic prostate cancer treatment. Moderator V. Brasiūnas S. Tiškevičius, J.Ušinskienė, R.Grigienė, R. Komiagienė, radiologists J. Asadauskienė, V. Brasiūnas, M. Rančelytė, A. Petrauskas, A. Česas, medical oncologists K. Slidevska, A. Vidrinskaitė, radiation oncologists Prof. M. Jievaltas, M. Kinčius, Ž. Kardelis, B. Šikšniūtė, A. Čekauskas, urologists D. Dasevičius, pathologist
14:45 – 15:45	Online test
15:45	Closing remarks. Prof. S. Jarmalaitė, Deputy Director for Research and Development of NCI, Acting Director of NCI Ž. Kardelis, A. Ulys, A. Zalimas

The registration will start on 1st of February, all participants will be able to register through this link: www.ebu2022.lt

Deputy Director for Research
and Development of NCI, Acting Director of NCI
Head of Oncourology Department
Coordinator of EBU

prof. dr. (HP) S. Jarmalaitė
Dr. A. Ulys
A. Žalimas